Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DORZOLAMIDE HCL

All products: Limited Use (codes 171, 172, 387)

Other products in the same Health Canada class (S01E, S01EC) — coverage varies; not interchangeable

  • Acetazolamide (Acetazolamide): general benefit, Not a benefit
  • Methazolamide (Neptazane): general benefit, Not a benefit
  • Brinzolamide (Azopt): limited Use 171, 172, 387
  • Brimonidine + brinzolamide (Simbrinza): limited Use 466, 393
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit

11 more in the class list below

Trusopt · DIN 02216205 · 2% · Oph Sol

Limited Use — Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.Discontinued 2025-12-08 · checked 2026-09-20
StatusLimited Use — Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Trusopt (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Trusopt · DIN 02216205 Manufacturer: Elvium Life Sciences; listing date 1996-12-19 Health Canada: Cancelled post market since 2025-12-08 · brand TRUSOPT · ATC S01EC03 DORZOLAMIDE · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2 % · company Elvium life sciences · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.4757 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20083 · Verify on the e-Formulary ↗ (DIN 02216205)

Source record
DIN 02216205: Trusopt Raw flags: sec12=Y, sec3=Y Item: 523600083; group id 623; item number 1590; lccId 00086; manufacturer id ELV Source form: Oph Sol; strength: 2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.1267; ministry $1.4757 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02216205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20083
Interchangeable products
Dorzolamide · DIN 02522373 · $1.4757 Jamp-Dorzolamide · DIN 02453347 · $1.4757 Med-Dorzolamide · DIN 02457210 · $1.4757 Sandoz Dorzolamide · DIN 02316307 · $1.4757
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Sandoz Dorzolamide (Dorzolamide Hydrochloride Ophthalmic Solution) 2% is indicated in the treatment of elevated intraocular pressure in patients with: • ocular hypertension • open-angle glaucoma 1.1 Pediatrics Pediatrics (<18 years of age): Safety and effectiveness in children have not been established. No data are available to Health Canada; therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00075318.PDF PM date: APR 17, 2024 Source product: SANDOZ DORZOLAMIDE; DIN 02316307; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.